Scholarlink

<p>Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML resistant or intolerant to prior therapy. Clinical trials have shown bosutinib is effective as first-line therapy for patients with CML as well as in later lines of therapy after prior TKI failure. Bosutinib has an established safety profile; however, as with all TKIs approved for the treatment of CML, there are adverse events (AEs) that require management. The safety profile of bosutinib is characterized by gastrointestinal, hematological, hepatic, and skin toxicities. Many of these AEs can be managed with dose adjustment strategies. In this podcast, the authors summarize data from some recent bosutinib publications and discuss implications for optimizing bosutinib treatment of patients with CML.</p><p><MediaObject ID="MOESM1"> <VideoObject FileRef="MediaObjects/11523_2024_1123_MOESM1_ESM.mp4" VideoID="5b65zsRj3jJDi8Znp_5BRC"> <Caption Language="En" xml:lang="en"> <CaptionContent> <p>Podcast Video (MP4 210846 KB)</p> </CaptionContent> </Caption> </VideoObject> </MediaObject></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bosutinib for the Treatment of CML—Using it Safely: a Podcast

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月17日

查看全文
  • Jeffrey H. Lipton,
  • Jorge E. Cortes

摘要

Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML resistant or intolerant to prior therapy. Clinical trials have shown bosutinib is effective as first-line therapy for patients with CML as well as in later lines of therapy after prior TKI failure. Bosutinib has an established safety profile; however, as with all TKIs approved for the treatment of CML, there are adverse events (AEs) that require management. The safety profile of bosutinib is characterized by gastrointestinal, hematological, hepatic, and skin toxicities. Many of these AEs can be managed with dose adjustment strategies. In this podcast, the authors summarize data from some recent bosutinib publications and discuss implications for optimizing bosutinib treatment of patients with CML.

Podcast Video (MP4 210846 KB)